Incyte Corporation (INCY)
Incyte is a US-based biopharmaceutical company that discovers and develops medicines to treat cancer and serious inflammatory conditions.
Is Incyte Corporation a good stock for a UK beginner?
The honest version: Incyte is a US-based biopharmaceutical company that discovers and develops medicines to treat cancer and serious inflammatory conditions.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Breakthrough success of a new drug in the pipeline
Failure of key research projects to reach the market
What does Incyte Corporation do?
Incyte focuses on finding new ways to treat complex diseases, primarily through its expertise in immunology and oncology. Sales of these specialised medicines to hospitals and pharmacies around the world bring in the revenue. Its fortunes hinge on how well their current drugs perform in the market and whether their pipeline of new treatments can successfully pass clinical trials.
On our factor screen it looks strongest on momentum and quality, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 38% over the year
- ✓Very profitable - turns about 28% of sales into profit
- ✓Low debt - a sturdier balance sheet
- ✓Strong return on shareholder money (ROE 31%)
- Quality screens high (81/100)
- Growth screens high (80/100)
- Momentum screens high (82/100)
- Strong profit margins indicate an efficient business model
- Impressive recent growth in both revenue and earnings
- Income screens low (16/100)
- Clinical trials may fail, leading to wasted research spending
- Government changes to drug pricing could hit future profits
- Competitors may launch more effective or cheaper treatments
What do Incyte Corporation's numbers mean?
How much money does Incyte Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Incyte Corporation pay a dividend?
No - Incyte Corporation doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Incyte Corporation report earnings, and how did recent quarters go?
Incyte Corporation is next scheduled to report on about 2026-10-27 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-28 | $2.15 | $3.09 | Beat +44% |
| 2026-04-28 | $1.34 | $1.81 | Beat +35% |
| 2026-02-10 | $1.92 | $1.80 | Missed -6% |
| 2025-10-28 | $1.64 | $2.26 | Beat +38% |
| 2025-07-29 | $1.47 | $1.57 | Beat +7% |
| 2025-04-29 | $1.03 | $1.16 | Beat +12% |
Across the last 6 quarters here, Incyte Corporation came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.
Agilent Technologies, Inc.What are the scenarios for Incyte Corporation?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Incyte Corporation?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Strong profit margins indicate an efficient business model
- Impressive recent growth in both revenue and earnings
- Lower volatility compared to the broader market
- Does not pay a dividend, so no regular income for shareholders
- High reliance on the success of a limited number of drugs
- The pharmaceutical industry is notoriously expensive and slow to innovate
- Clinical trials may fail, leading to wasted research spending
- Government changes to drug pricing could hit future profits
- Competitors may launch more effective or cheaper treatments
The write-up's own warning lights — if these start happening, the case above changes.
- A major, unexpected failure in a late-stage clinical trial
- A significant change in government healthcare policy affecting drug reimbursement
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.